病媒生物监测预警研究进展

刘起勇

刘起勇. 病媒生物监测预警研究进展[J]. 疾病监测, 2018, 33(2): 123-128. doi: 10.3784/j.issn.1003-9961.2018.02.005
引用本文: 刘起勇. 病媒生物监测预警研究进展[J]. 疾病监测, 2018, 33(2): 123-128. doi: 10.3784/j.issn.1003-9961.2018.02.005
Liu Qiyong. Research progress on the vector surveillance and early-warning[J]. Disease Surveillance, 2018, 33(2): 123-128. doi: 10.3784/j.issn.1003-9961.2018.02.005
Citation: Liu Qiyong. Research progress on the vector surveillance and early-warning[J]. Disease Surveillance, 2018, 33(2): 123-128. doi: 10.3784/j.issn.1003-9961.2018.02.005

病媒生物监测预警研究进展

doi: 10.3784/j.issn.1003-9961.2018.02.005
基金项目: 

国家重点研发计划(No.2016YFC1200802,2016YFC1200502)

Research progress on the vector surveillance and early-warning

Funds: 

This study was supported by the fund for National Key Research and Development Project(No. 2016YFC1200802, 2016YFC1200502)

  • 摘要: 病媒生物监测预警是其可持续精准控制的前提和基础,事关媒介生物传染病预防控制的成败。基于病媒生物阈值的定量评估和基于多学科模型的预测,已成为当前病媒生物监测预警最常用的方法。随着病媒生物鉴定和监测技术的发展,多学科研究方法的引入,伴随着大数据和云平台等新信息技术的兴起,病媒生物监测预警技术进一步得到提升,并向着基于多学科的综合模型构建和预警系统研发方向不断发展。本文就当前国内外病媒生物监测预警的策略、措施、方法、技术及未来发展趋势进行综述,为媒介生物传染病的科学防控提供参考依据。
  • [1] O'BrienKL,WolfsonLJ,WattJP,etal.BurdenofdiseasecausedbyStreptococcuspneumoniaeinchildrenyoungerthan5years:globalestimates[J].Lancet,2009,374(9693):893-902.DOI: 10.1016/S0140-6736(09)61204-6.
    [2] WHO.Pneumococcalvaccines:WHOpositionpaper-2012[J].WklyEpidemiolRec,2012,87(14):129-144.
    [3] 中华人民共和国卫生部.中国妇幼卫生事业发展报告(2011)[EB/OL].(2011-09-21)[2018-01-10].http://www.gov.cn/gzdt/att/att/site1/20110921/001e3741a4740fe3bdab01.pdf.MOH.ThedevelopmentreportonChinesematenalandchildrenhealth(2011)[EB/OL].(2011-09-21)[2018-01-10].http://www.gov.cn/gzdt/att/att/site1/20110921/001e3741a4740fe3bdab01.pdf.
    [4] 孙谨芳,么鸿雁,于石成,等.1990年和2010年中国3种细菌性脑膜炎疾病负担情况[J].疾病监测,2015,30(12):1008-1013.DOI: 10.3784/j.issn.1003-9961.2015.12.006.SunJF,YaoHY,YuSC,etal.DiseaseBurdenofthreekindsofbacterialmeningitisinChina,1990and2010[J].DisSurveill,2015,30(12):1008-1013.DOI:10.3784/j.issn.1003-9961.2015.12.006.
    [5] 黄广丽,石庆生,陈海霞,等.肺炎患儿咽部吸出物检测及细菌耐药性分析[J].河北医科大学学报,2016,37(1):40-43.DOI: 10.3969/j.issn.1007-3205.2016.01.011.HuangGL,ShiQS,ChenHX,etal.Bacteriadetectioninsputumandanalysisofbacterialresistanceinchildhoodpneumonia[J].JHebeiMedUniv,2016,37(1):40-43.DOI:10.3969/j.issn.1007-3205.2016.01.011.
    [6] 刘又宁,陈民钧,赵铁梅,等.中国城市成人社区获得性肺炎665例病原学多中心调查[J].中华结核和呼吸杂志,2006,29(1):3-8.DOI: 10.3760/j:issn:1001-0939.2006.01.003.LiuYN,ChenMJ,ZhaoTM,etal.Amulticentrestudyonthepathogenicagentsin665adultpatientswithcommunity-acquiredpneumoniaincitiesofChina[J].ChinJTubercRespirDis,2006,29(1):3-8.DOI:10.3760/j:issn:1001-0939.2006.01.003.
    [7] WHO.Meetingoftheimmunizationstrategicadvisorygroupofexperts,November2007-conclusionsandrecommendations[J].WklyEpidemiolRec,2008,83(1):1-16.
    [8] PlotkinSA,OrensteinWA,OffitPA.Vaccines[M].6thed.Amsterdam:Elsevier,2013:542.
    [9] ParkIH,PritchardDG,CarteeR,etal.Discoveryofanewcapsularserotype(6C)withinserogroup6ofStreptococcuspneumoniae[J].JClinMicrobiol,2007,45(4):1225-1233.DOI: 10.1128/JCM.02199-06.
    [10] PenningtonJE.Treatingrespiratoryinfectionsintheeraofcostcontrol[J].AmFamPhysician,1986,33(2):153-160.
    [11] 张雪梅.肺炎链球菌自然转化机制的研究进展[J].国外医学临床生物化学与检验学分册,2002,23(6):348-350.DOI: 10.3969/j.issn.1673-4130.2002.06.016.ZhangXM.Researchprogressonnaturaltransformationofstreptococcuspneumoniae[J].ForMedSci,2002,23(6):348-350.DOI:10.3969/j.issn.1673-4130.2002.06.016.
    [12] 孟江萍,尹一兵.肺炎链球菌致病机理的最新研究进展[J].微生物学杂志,2002,22(2):39-41.DOI: 10.3969/j.issn.1005-7021.2002.02.015.MengJP,YinYB.ThenewestadvanceinpathogenicmechanismofStreptococcuspneumoniae[J].JMicrobiol,2002,22(2):39-41.DOI:10.3969/j.issn.1005-7021.2002.02.015.
    [13] 陈保德.肺炎链球菌致病的分子机理[J].国外医学临床生物化学与检验学分册,2002,23(6):362-364.DOI: 10.3969/j.issn.1673-4130.2002.06.022.ChenBD.ThemolecularmechanismofStreptococcuspneumoniaedisease[J].ForMedSci,2002,23(6):362-364.DOI:10.3969/j.issn.1673-4130.2002.06.022.
    [14] 黄彬,陈茶.肺炎链球菌蛋白质类的毒力因子[J].国外医学临床生物化学与检验学分册,1999,20(2):71-73.HuangB,ChenC.ThevirulencefactorofStreptococcuspneumoniaeprotein.[J].ForMedSci,1999,20(2):71-73.
    [15] 鲜墨,吴忠道.肺炎链球菌感染的流行病学及毒力因子研究进展[J].热带医学杂志,2006,6(6):740-742,693.DOI: 10.3969/j.issn.1672-3619.2006.06.045.XianM,WuZD.EpidemiologicalstudyofStreptococcuspneumoniaeinfectionandthedevelopmentofvirulencefactors[J].JTropMed,2006,6(6):740-742,693.DOI:10.3969/j.issn.1672-3619.2006.06.045.
    [16] Meerveld-EgginkA,deWeerdtO,vanVelzen-BladH,etal.ResponsetoconjugatepneumococcalandHaemophilusinfluenzaetypebvaccinesinasplenicpatients[J].Vaccine,2011,29(4):675-680.DOI: 10.1016/j.vaccine.2010.11.034.
    [17] HausdorffWP,BryantJ,ParadisoPR,etal.Whichpneumococcalserogroupscausethemostinvasivedisease:implicationsforconjugatevaccineformulationanduse,partI[J].ClinInfectDis,2000,30(1):100-121.DOI: 10.1086/313608.
    [18] Romero-SteinerS,LibuttiD,PaisLB,etal.StandardizationofanopsonophagocyticassayforthemeasurementoffunctionalantibodyactivityagainstStreptococcuspneumoniaeusingdifferentiatedHL-60cells[J].ClinDiagnLabImmunol,1997,4(4):415-422.
    [19] WinkelsteinJA,SmithMR,ShinHS.TheroleofC3asanopsoninintheearlystagesofinfection[J].ProcSocExpBiolMed,1975,149(2):397-401.DOI: 10.3181/00379727-149-38815.
    [20] Romero-SteinerS,FraschCE,CarloneG,etal.Useofopsonophagocytosisforserologicalevaluationofpneumococcalvaccines[J].ClinVaccineImmunol,2006,13(2):165-169.DOI: 10.1128/CVI.13.2.165-169.2006.
    [21] TaylorSN,SandersCV.Unusualmanifestationsofinvasivepneumococcalinfection[J].AmJMed,1999,107(1Suppl1):12-27.DOI: 10.1016/S0002-9343(99)00103-5.
    [22] 姚开虎,赵顺英,杨永弘.儿童肺炎链球菌坏死性肺炎[J].中国循证儿科杂志,2007,2(6):449-454.DOI: 10.3969/j.issn.1673-5501.2007.06.008.YaoKH,ZhaoSY,YangYH.Streptococcusnecrotizingpneumoniainchildren[J].ChinJEvid-BasedPediatr,2007,2(6):449-454.DOI:10.3969/j.issn.1673-5501.2007.06.008.
    [23] 俞桑洁,王辉,沈叙庄,等.肺炎链球菌临床检验规程的共识[J].中华检验医学杂志,2012,35(12):1066-1072.DOI: 10.3760/cma.j.issn.1009-9158.2012.12.003.YuSJ,WangH,ShenXZ,etal.ConsensusofclinicallaboratoryproceduresforStreptococcuspneumoniae[J].ChinJLabMed,2012,35(12):1066-1072.DOI:10.3760/cma.j.issn.1009-9158.2012.12.003.
    [24] 中华医学会儿科学分会呼吸学组,《中华儿科杂志》编辑委员会.儿童社区获得性肺炎管理指南(2013修订)(上)[J].中华儿科杂志,2013,51(10):745-752.DOI: 10.3760/cma.j.issn.0578-1310.2013.10.006.Chineseacademyofpediatrics,respiratorygroup,editorialboardofChinesejournalofpediatrics.Guidelinesforthemanagementofchildren'scommunityacquiredpneumonia(2013)(Firstpart)[J].ChinJPediatr,2013,51(10):745-752.DOI:10.3760/cma.j.issn.0578-1310.2013.10.006.
    [25] LyuS,YaoKH,DongF,etal.VaccineserotypesofStreptococcuspneumoniaewithhigh-levelantibioticresistanceisolatedmorefrequentlysevenyearsafterthelicensureofPCV7inBeijing[J].PediatrInfectDisJ,2016,35(3):316-321.DOI: 10.1097/INF.0000000000001000.
    [26] SongJH.Advancesinpneumococcalantibioticresistance[J].ExpertRevRespirMed,2013,7(5):491-498.DOI: 10.1586/17476348.2013.816572.
    [27] 姚开虎,王立波,赵根明,等.四家儿童医院住院肺炎病例肺炎链球菌分离株的耐药性监测[J].中国当代儿科杂志,2008,10(3):275-279.YaoKH,WangLB,ZhaoGM,etal.SurveillanceofantibioticresistanceofStreptococcuspneumoniaeisolatedfromhospitalizedpatientswithpneumoniainfourchildren'shospitalsinChina[J].ChinJContempPediatr,2008,10(3):275-279.
    [28] 王利民,吴俊琪,方寅飞.学龄前儿童下呼吸道感染肺炎链球菌的流行病学特征与耐药性变迁[J].中国卫生检验杂志,2016,26(9):1349-1352.WangLM,WuJQ,FangYF.EpidemiologicalcharacteristicsanddrugresistancechangesofStreptococcuspneumoniaeinlowerrespiratorytractinfectionofpreschoolchildren[J].ChinJHealthLabTechnol,2016,26(9):1349-1352.
    [29] 王启,张菲菲,赵春江,等.2010-2011年中国肺炎链球菌耐药性和血清型研究[J].中华结核和呼吸杂志,2013,36(2):106-112.DOI: 10.3760/cma.j.issn.1001-0939.2013.02.009.WangQ,ZhangFF,ZhaoCJ,etal.AntimicrobialresistanceandserotypedistributionofStreptococcuspneumoniaeisolatedfrommulticentersacrossChina,2010-2011[J].ChinJTubercRespirDis,2013,36(2):106-112.DOI:10.3760/cma.j.issn.1001-0939.2013.02.009.
    [30] KangLH,LiuMJ,XuWC,etal.MolecularepidemiologyofpneumococcalisolatesfromchildreninChina[J].SaudiMedJ,2016,37(4):403-413.DOI: 10.15537/smj.2016.4.14507.
    [31] YaoKH,WangLB,ZhaoGM,etal.PneumococcalserotypedistributionandantimicrobialresistanceinChinesechildrenhospitalizedforpneumonia[J].Vaccine,2011,29(12):2296-2301.DOI: 10.1016/j.vaccine.2011.01.027.
    [32] KimSH,SongJH,ChungDR,etal.ChangingtrendsinantimicrobialresistanceandserotypesofStreptococcuspneumoniaeisolatesinAsiancountries:anAsianNetworkforSurveillanceofResistantPathogens(ANSORP)study[J].AntimicrobAgentsChemother,2012,56(3):1418-1426.DOI: 10.1128/AAC.05658-11.
    [33] WHO.Pneumococcalconjugatevaccineforchildhoodimmunization-WHOpositionpaper[J].WklyEpidemiolRec,2007,82(12):93-104.
    [34] YaoKH,YangYH.StreptococcuspneumoniaediseasesinChinesechildren:past,presentandfuture[J].Vaccine,2008,26(35):4425-4433.DOI: 10.1016/j.vaccine.2008.06.052.
    [35] MahonBE,EhrensteinV,NrgaardM,etal.Perinatalriskfactorsforhospitalizationforpneumococcaldiseaseinchildhood:apopulation-basedcohortstudy[J].Pediatrics,2007,119(4):e804-812.DOI: 10.1542/peds.2006-2094.
    [36] AdvisoryCommitteeonImmunizationPractices.Preventingpneumococcaldiseaseamonginfantsandyoungchildren:recommendationsoftheadvisorycommitteeonimmunizationpractices(ACIP)[J].MMWRRecommRep,2000,49(RR-9):i-v,1-35.
    [37] BurgosJ,LarrosaMN,MartinezA,etal.Impactofinfluenzaseasonandenvironmentalfactorsontheclinicalpresentationandoutcomeofinvasivepneumococcaldisease[J].EurJClinMicrobiolInfectDis,2015,34(1):177-186.DOI: 10.1007/s10096-014-2221-9.
    [38] PereirI,Dez-DomingoJ,SegarraL,etal.RiskfactorsforinvasivediseaseamongchildreninSpain[J].JInfect,2004,48(4):320-329.DOI: 10.1016/j.jinf.2003.10.015.
    [39] KadiogluA,WeiserJN,PatonJC,etal.TheroleofStreptococcuspneumoniaevirulencefactorsinhostrespiratorycolonizationanddisease[J].NatRevMicrobiol,2008,6(4):288-301.DOI: 10.1038/nrmicro1871.
    [40] RoyS,KnoxK,SegalS,etal.MBLgenotypeandriskofinvasivepneumococcaldisease:acase-controlstudy[J].Lancet,2002,359(9317):1569-1573.DOI: 10.1016/S0140-6736(02)08516-1.
    [41] MandellLA,WunderinkRG,AnzuetoA,etal.InfectiousdiseasessocietyofAmerica/Americanthoracicsocietyconsensusguidelinesonthemanagementofcommunity-acquiredpneumoniainadults[J].ClinInfectDis,2007,44Suppl2:S27-72.DOI: 10.1086/511159.
    [42] CDC.Preventionofpneumococcaldisease:recommendationsoftheAdvisoryCommitteeonImmunizationPractices(ACIP)[J].MMWRRecommRep,1997,46(RR-8):i-iv,1-24.
    [43] EuropeanCDC.Technicalreportofthescientificpanelonvaccinesandimmunisation:useofpneumococcalpolysaccharidevaccineforsubjectsover65yearsofageduringaninterpandemicperiodStockholm,January2007[EB/OL].(2007-01)[2018-01-18].https://ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/0701_TER_Use_of_pneumococcal_polysaccharide_vaccine.pdf.
    [44] FeikinDR,FeldmanC,SchuchatA,etal.GlobalstrategiestopreventbacterialpneumoniainadultswithHIVdisease[J].LancetInfectDis,2004,4(7):445-455.DOI: 10.1016/S1473-3099(04)01060-6.
    [45] CDC.Recommendedadultimmunizationschedule-UnitedStates,October2006-September2007[J/OL][2006-10-13].MMWR,2006,55:(40)Q1-Q4.https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5540a10.htm.
    [46] RobinsonKA,BaughmanW,RothrockG,etal.EpidemiologyofinvasiveStreptococcuspneumoniaeinfectionsintheUnitedStates,1995-1998:opportunitiesforpreventionintheconjugatevaccineera[J].JAMA,2001,285(13):1729-1735.DOI: 10.1001/jama.285.13.1729.
    [47] NuortiJP,ButlerJC,FarleyMM,etal.Cigarettesmokingandinvasivepneumococcaldisease[J].NEnglJMed,2000,342(10):681-689.DOI: 10.1056/NEJM200003093421002.
    [48] BenderJM,AmpofoK,KorgenskiK,etal.PneumococcalnecrotizingpneumoniainUtah:doesserotypematter?[J].ClinInfectDis,2008,46(9):1346-1352.DOI: 10.1086/586747.
    [49] TalbotTR,HartertTV,MitchelE,etal.Asthmaasariskfactorforinvasivepneumococcaldisease[J].NEnglJMed,2005,352(20):2082-2090.DOI: 10.1056/NEJMoa044113.
    [50] SethiS,MurphyTF.Infectioninthepathogenesisandcourseofchronicobstructivepulmonarydisease[J].NEnglJMed,2008,359(22):2355-2365.DOI: 10.1056/NEJMra0800353.
    [51] TalbotTR,PoehlingKA,HartertTV,etal.Seasonalityofinvasivepneumococcaldisease:temporalrelationtodocumentedinfluenzaandrespiratorysyncytialviralcirculation[J].AmJMed,2005,118(3):285-291.DOI: 10.1016/j.amjmed.2004.09.016.
    [52] ToschkeAM,ArenzS,vonKriesR,etal.Notemporalassociationbetweeninfluenzaoutbreaksandinvasivepneumococcalinfections[J].ArchDisChild,2008,93(3):218-220.DOI: 10.1136/adc.2006.098996.
    [53] MorensDM,TaubenbergerJK,FauciAS.Predominantroleofbacterialpneumoniaasacauseofdeathinpandemicinfluenza:implicationsforpandemicinfluenzapreparedness[J].JInfectDis,2008,198(7):962-970.DOI: 10.1086/591708.
    [54] CDC.VaccinepreventabledeathsandtheGlobalImmunizationVisionandStrategy,2006-2015[J].MMWRMorbMortalWklyRep,2006,55(18):511-515.
    [55] WHO.EstimatedHibandpneumococcaldeathsforchildrenunder5yearsofage,2008[R].Geneva:WHO,2013.
    [56] WalkerCLF,RudanI,LiuL,etal.Globalburdenofchildhoodpneumoniaanddiarrhoea[J].Lancet,2013,381(9875):1405-1416.DOI: 10.1016/S0140-6736(13)60222-6.
    [57] NaghaviM,AbajobirAA,AbbafatiC,etal.Global,regional,andnationalage-sexspecificmortalityfor264causesofdeath,1980-2016:asystematicanalysisfortheGlobalBurdenofDiseaseStudy2016[J].Lancet,2017,390(10100):1151-1210.DOI: 10.1016/S0140-6736(17)32152-9.
    [58] IsaacmanDJ,McIntoshED,ReinertRR.BurdenofinvasivepneumococcaldiseaseandserotypedistributionamongStreptococcuspneumoniaeisolatesinyoungchildreninEurope:impactofthe7-valentpneumococcalconjugatevaccineandconsiderationsforfutureconjugatevaccines[J].IntJInfectDis,2010,14(3):e197-209.DOI: 10.1016/j.ijid.2009.05.010.
    [59] KarstaedtAS,KhoosalM,Crewe-BrownHH.PneumococcalbacteremiaduringadecadeinchildreninSoweto,SouthAfrica[J].PediatrInfectDisJ,2000,19(5):454-457.
    [60] CuttsFT,ZamanSMA,EnwereG,etal.Efficacyofnine-valentpneumococcalconjugatevaccineagainstpneumoniaandinvasivepneumococcaldiseaseinTheGambia:randomised,double-blind,placebo-controlledtrial[J].Lancet,2005,365(9465):1139-1146.DOI: 10.1016/S0140-6736(05)71876-6.
    [61] RocaA,SigaqueB,QuintL,etal.Invasivepneumococcaldiseaseinchildren5yearsofageinruralMozambique[J].TropMedIntHealth,2006,11(9):1422-1431.DOI: 10.1111/j.1365-3156.2006.01697.x.
    [62] BjornsonG,ScheifeleD,BinderF,etal.Population-basedincidencerateofinvasivepneumococcalinfectioninchildren:Vancouver,1994-1998[J].CanCommunDisRep,2000,26(18):149-151;discussion151-152.
    [63] EskolaJ,TakalaAK,KelaE,etal.EpidemiologyofinvasivepneumococcalinfectionsinchildreninFinland[J].JAMA,1992,268(23):3323-3327.DOI: 10.1001/jama.1992.03490230053027.
    [64] vonKriesR,SiedlerA,SchmittHJ,etal.ProportionofinvasivepneumococcalinfectionsinGermanchildrenpreventablebypneumococcalconjugatevaccines[J].ClinInfectDis,2000,31(2):482-487.DOI: 10.1086/313984.
    [65] CDC.Epidemiologyandpreventionofvaccine-preventablediseases-pneumococcaldisease[J/OL].[2018-01-20].https://www.cdc.gov/vaccines/pubs/pinkbook/pneumo.html.
    [66] BerezinEN,IazzettiMA.Evaluationoftheincidenceofoccultbacteremiaamongchildrenwithfeverofunknownorigin[J].BrazJInfectDis,2006,10(6):396-399.DOI: 10.1590/S1413-86702006000600007.
    [67] AvnerJR,BakerMD.Occultbacteremiainthepost-pneumococcalconjugatevaccineera:doesthebloodculturestophere?[J].AcadEmergMed,2009,16(3):258-260.DOI: 10.1111/j.1553-2712.2008.00345.x.
    [68] AlpernER,AlessandriniEA,BellLM,etal.Occultbacteremiafromapediatricemergencydepartment:currentprevalence,timetodetection,andoutcome[J].Pediatrics,2000,106(3):505-511.DOI: 10.1542/peds.106.3.505.
    [69] WHO.GLOBALhealthestimates2015summarytables:globalDALYsbycause,ageandsex,2000-2015[EB/OL].(2016-12)[2018-01-18].http://www.who.int/entity/healthinfo/global_burden_disease/GHE2015_DALY_Global_2000_2015.xls?ua=1
    [70] GBD2015DALYs,CollaboratorsHALE.Global,regional,andnationaldisability-adjustedlife-years(DALYs)for315diseasesandinjuriesandhealthylifeexpectancy(HALE),1990-2015:asystematicanalysisfortheGlobalBurdenofDiseaseStudy2015[J].Lancet,2016,388(10053):1603-1658.DOI: 10.1016/S0140-6736(16)31460-X.
    [71] MurrayCJL,VosT,LozanoR,etal.Disability-adjustedlifeyears(DALYs)for291diseasesandinjuriesin21regions,1990-2010:asystematicanalysisfortheGlobalBurdenofDiseaseStudy2010[J].Lancet,2012,380(9859):2197-2223.DOI: 10.1016/S0140-6736(12)61689-4.
    [72] WeyckerD,StruttonD,EdelsbergJ,etal.ClinicalandeconomicburdenofpneumococcaldiseaseinolderUSadults[J].Vaccine,2010,28(31):4955-4960.DOI: 10.1016/j.vaccine.2010.05.030.
    [73] PetitG,deWalsP,LawB,etal.EpidemiologicalandeconomicburdenofpneumococcaldiseaseinCanadianchildren[J].CanJInfectDis,2003,14(4):215-220.DOI: 10.1155/2003/781794.
    [74] 国家卫生和计划生育委员会.2015中国卫生和计划生育统计年鉴[M].北京:中国协和医科大学出版社,2015.NationalHealthandFamilyPlanningCommissionofthePeople'sRepublicofChina.Chinahealthandfamilyplanningstatisticalyearbook,2015[M].Beijing:Chinaunionmedicaluniversitypress,2015.
    [75] 宁桂军,王旭霞,刘世文,等.2015-2016年甘肃省白银市5岁以下儿童社区获得性肺炎疾病负担回顾性调查[J].中国疫苗和免疫,2017,23(1):18-21,12.NingGJ,WangXX,LiuSW,etal.Retrospectiveinvestigationofthediseaseburdenofcommunityacquiredpneumoniaamongchildrenunder5yearsoldinBaiyincityofGansuprovince,2015-2016[J].ChinJVaccinesImmuniz,2017,23(1):18-21,12.
    [76] NingGJ,WangXX,WuD,etal.Theetiologyofcommunityacquiredpneumoniaamongchildrenunder5yearsofageinmainlandChina,2001-2015:asystematicreview[J].HumVaccinImmunother,2017,13(11):2742-2750.DOI: 10.1080/21645515.2017.1371381.
    [77] TaoLL,HuBJ,HeLX,etal.Etiologyandantimicrobialresistanceofcommunity-acquiredpneumoniainadultpatientsinChina[J].ChinMedJ(Engl),2012,125(17):2967-2972.DOI: 10.3760/cma.j.issn.0366-6999.2012.17.002.
    [78] HuangHH,ZhangYY,XiuQY,etal.Community-acquiredpneumoniainShanghai,China:microbialetiologyandimplicationsforempiricaltherapyinaprospectivestudyof389patients[J].EurJClinMicrobiolInfectDis,2006,25(6):369-374.DOI: 10.1007/s10096-006-0146-7.
    [79] ZhouMG,WangHD,ZhuJ,etal.Cause-specificmortalityfor240causesinChinaduring1990-2013:asystematicsubnationalanalysisfortheGlobalBurdenofDiseaseStudy2013[J].Lancet,2016,387(10015):251-272.DOI: 10.1016/S0140-6736(15)00551-6.
    [80] LimcangcoMRT,SaloleEG,ArmourCL.EpidemiologyofHaemophilusinfluenzaetypebmeningitisinManila,Philippines,1994to1996[J].PediatrInfectDisJ,2000,19(1):7-11.
    [81] MahmoudR,MahmoudM,BadrinathP,etal.PatternofmeningitisinAl-Ainmedicaldistrict,UnitedArabEmirates-adecadalexperience(1990-99)[J].JInfect,2002,44(1):22-25.DOI: 10.1053/jinf.2001.0937.
    [82] HussainIHM,SofiahA,OngLC,etal.HaemophilusinfluenzaemeningitisinMalaysia[J].PediatrInfectDisJ,1998,17(9Suppl):S189-190.
    [83] TaylorHG,MichaelsRH,MazurPM,etal.Intellectual,neuropsychological,andachievementoutcomesinchildrensixtoeightyearsafterrecoveryfromHaemophilusinfluenzaemeningitis[J].Pediatrics,1984,74(2):198-205.
    [84] 卫生福利部统计处.全民健康保险医疗统计[EB/OL].2017.http://www.mohw.gov.tw/CHT/DOS/Statistic.aspx?f_list_no=312fod_list_no=1604.StatisticsDepartmentofHealthandWelfare.Statisticsofmedicalcareandhealthinsurance[EB/OL].2017.http://www.mohw.gov.tw/CHT/DOS/Statistic.aspx?f_list_no=312fod_list_no=1604.
    [85] 卫生福利部统计处.死因统计[EB/OL].2017.http://www.mohw.gov.tw/CHT/DOS/Statistic.aspx?f_list_no=312fod_list_no=1610.StatisticsDepartmentofHealthandWelfare.Causeofdeath[EB/OL].2017.http://www.mohw.gov.tw/CHT/DOS/Statistic.aspx?f_list_no=312fod_list_no=1610.
    [86] TingYT,LuCY,ShaoPL,etal.EpidemiologyofcommunityacquiredbacteremiaamonginfantsinamedicalcenterinTaiwan,2002-2011[J].JMicrobiolImmunolInfect,2015,48(4):413-418.DOI: 10.1016/j.jmii.2013.10.005.
    [87] 王进东,张再兴,孙静涛,等.唐山地区2008-2013年儿童急性中耳炎流行病学调查[J].中国妇幼保健,2015,30(6):939-941.DOI: 10.7620/zgfybj.j.issn.1001-4411.2015.06.47.WangJD,ZhangZX,SunJT,etal.Anepidemiologicalinvestigationofacuteotitismediainchildrenfrom2008to2013inTangshanprefecture[J].MaternalandChildHealthCareofChina,2015,30(6):939-941.DOI:10.7620/zgfybj.j.issn.1001-4411.2015.06.47.
    [88] 刘俊英,赵英,张爱凤,等.唐山地区儿童急性中耳炎常见病原菌及药物敏感性分析[J].现代预防医学,2014,41(19):3517-3519,3529.LiuJY,ZhaoY,ZhangAF,etal.AnalysisofthecommonpathogensofacuteotitismediaandtheirdrugsensitivityinchildreninTangshan[J].ModPreventMed,2014,41(19):3517-3519,3529.
    [89] 景阳,韩想利,王宇娟,等.西安地区290例儿童急性中耳炎分泌物细菌培养及药敏分析[J].检验医学与临床,2016,13(4):457-459.DOI: 10.3969/j.issn.1672-9455.2016.04.009.JingY,HanXL,WangYJ,etal.Analysisofthe260commonpathogensofacuteotitismediaandtheirdrugsensitivityinchildreninXi'an[J].LaborMedClin,2016,13(4):457-459.DOI:10.3969/j.issn.1672-9455.2016.04.009.
    [90] InstituteforHealthMetricsandEvaluation.Globalhealthdataexchange[EB/OL].[2018-01-18].http://ghdx.healthdata.org/gbd-2016.
    [91] LiY,AnZJ,YinDP,etal.Diseaseburdenofcommunityacquiredpneumoniaamongchildrenunder5yoldinChina:Apopulationbasedsurvey[J].HumVaccinImmunother,2017,13(7):1681-1687.DOI: 10.1080/21645515.2017.1304335.
    [92] 周勇,陈泽玲,王缃赟.珠海市社区获得性肺炎疾病负担研究[J].深圳中西医结合杂志,2016,26(20):81-82.DOI: 10.16458/j.cnki.1007-0893.2016.20.040.ZhouY,ChenZL,WangXY.StudyontheburdenofcommunityacquiredpneumoniainZhuhaicity[J].ShenzhenJIntTraditChinWestMed,2016,26(20):81-82.DOI:10.16458/j.cnki.1007-0893.2016.20.040.
    [93] 邸明芝,曹迎,黄辉,等.248例成人社区获得性肺炎病例疾病负担调查[J].现代预防医学,2014,41(14):2560-2562,2584.DiMZ,CaoY,HuangH,etal.Investigationontheexpensesof248adultpatientswithcommunity-acquiredpneumoniainDongchengdistrict,Beijing[J].ModPreventMed,2014,41(14):2560-2562,2584.
    [94] 宋圣帆.肺炎链球菌疾病费用研究与七价肺炎球菌结合疫苗的卫生经济学评价[D].上海:复旦大学,2013.SongSF.ThestudyonburdenofpneumococcaldiseasesandcosteffectivenessanalysisofpneumococcalconjugatevaccineinChina[D].Shanghai:FudanUniversity,2013.
    [95] 朱琳,刘国恩,李冬美,等.儿童七价肺炎球菌结合疫苗的成本效果分析[J].中国卫生经济,2013,32(4):71-75.DOI: 10.7664/CHE20130423.ZhuL,LiuGN,LiDM,etal.Ecomomicevaluationof7-valentpneumococcalconjugatevaccine(PCV7)[J].ChinHealthEconom,2013,32(4):71-75.DOI:10.7664/CHE20130423.
    [96] 刘文婷.部分地区三种主要细菌性脑膜炎病例经济负担调查[D].北京:中国疾病预防控制中心,2016.LiuWT.Economicburdenofthreemajorbacterialmeningitiscasesinsomeareas[D].Beijing:ChineseCenterforDiseaseControlandPrevention,2016.
    [97] WuDBC,RobertsCS,HuangYC,etal.Aretrospectivestudytoassesstheepidemiologicalandeconomicburdenofpneumococcaldiseasesinadultsaged50yearsandolderinTaiwan[J].JMedEcon,2014,17(5):312-319.DOI: 10.3111/13696998.2014.898644.
    [98] JohnsonHL,Deloria-KnollM,LevineOS,etal.Systematicevaluationofserotypescausinginvasivepneumococcaldiseaseamongchildrenunderfive:thepneumococcalglobalserotypeproject[J].PLoSMed,2010,7(10):e1000348.DOI: 10.1371/journal.pmed.1000348.
    [99] PilishviliT,LexauC,FarleyMM,etal.Sustainedreductionsininvasivepneumococcaldiseaseintheeraofconjugatevaccine[J].JInfectDis,2010,201(1):32-41.DOI: 10.1086/648593.
    [100] KaplanSL,BarsonWJ,LinPL,etal.Serotype19Aisthemostcommonserotypecausinginvasivepneumococcalinfectionsinchildren[J].Pediatrics,2010,125(3):429-436.DOI: 10.1542/peds.2008-1702.
    [101] KaplanSL,BarsonWJ,LinPL,etal.Earlytrendsforinvasivepneumococcalinfectionsinchildrenaftertheintroductionofthe13-valentpneumococcalconjugatevaccine[J].PediatrInfectDisJ,2013,32(3):203-207.DOI: 10.1097/INF.0b013e318275614b.
    [102] IrohTamPY,ThielenBK,ObaroSK,etal.ChildhoodpneumococcaldiseaseinAfrica-asystematicreviewandmetaanalysisofincidence,serotypedistribution,andantimicrobialsusceptibility[J].Vaccine,2017,35(15):1817-1827.DOI: 10.1016/j.vaccine.2017.02.045.
    [103] FosterD,KnoxK,WalkerAS,etal.Invasivepneumococcaldisease:epidemiologyinchildrenandadultspriortoimplementationoftheconjugatevaccineintheOxfordshireregion,England[J].JMedMicrobiol,2008,57(Pt4):480-487.DOI: 10.1099/jmm.0.47690-0.
    [104] MotlovaJ,BenesC,KrizP.IncidenceofinvasivepneumococcaldiseaseintheCzechRepublicandserotypecoveragebyvaccines,1997-2006[J].EpidemiolInfect,2009,137(4):562-569.DOI: 10.1017/S0950268808001301.
    [105] ChenY,DengW,WangSM,etal.BurdenofpneumoniaandmeningitiscausedbyStreptococcuspneumoniaeinChinaamongchildrenunder5yearsofage:asystematicliteraturereview[J].PLoSOne,2011,6(11):e27333.DOI: 10.1371/journal.pone.0027333.
    [106] 韦宁,安志杰,王华庆.中国18岁人群肺炎球菌相关病例中肺炎球菌血清型分布的系统评价[J].中国疫苗和免疫,2014,20(6):547-555.WeiN,AnZJ,WangHQ,etal.AsystematicreviewoftheserotypedistributionofStreptococcuspneumoniae(pneumococcus)amongallcasesunder18yearsoldofpneumococcalinfectioninChina[J].ChinJVaccinesImmun,2014,20(6):547-555.
    [107] 傅锦坚,丁燕玲,徐少林,等.中国内地健康儿童鼻咽携带肺炎链球菌及其血清型分布的系统评价[C]//第七届中国临床微生物学大会暨微生物学与免疫学论坛论文汇编.宁波:中国微生物学会临床微生物学专业委员会,医学参考报社,宁波大学,宁波大学医学院附属医院,2016.FuJJ,DingYL,XuSL,etal.AsystematicreviewofhealthychildrennasopharyngealcarrystreptococcuspneumoniaeandserotypedistributioninmainlandChina[C]//The7thChinaclinicalmicrobiologyconferenceproceedingsandmicrobiologyandimmunologyBBS.Ningbo:ClinicalmicrobiologyprofessionalcommitteeofChinasocietyformicrobiology,Medicalreferencenewspaper,Ningbouniversity,Ningbouniversitymedicalschoolaffiliatedhospital,2016.
    [108] LyuS,HuHL,YangYH,etal.AsystematicreviewaboutStreptococcuspneumoniaeserotypedistributioninchildreninmainlandofChinabeforethePCV13waslicensed[J].ExpertRevVaccines,2017,16(10):997-1006.DOI: 10.1080/14760584.2017.1360771.
    [109] MacLeodCM,HodgesRG,HeidelbergerM,etal.Preventionofpneumococcalpneumoniabyimmunizationwithspecificcapsularpolysaccharides[J].JExpMed,1945,82(6):445-465.DOI: 10.1084/jem.82.6.445.
    [110] NieminenT,KyhtyH,VirolainenA,etal.CirculatingantibodysecretingcellresponsetoparenteralpneumococcalvaccinesasanindicatorofasalivaryIgAantibodyresponse[J].Vaccine,1998,16(2/3):313-319.DOI: 10.1016/S0264-410X(97)00162-X.
    [111] SkinnerJM,IndrawatiL,CannonJ,etal.Pre-clinicalevaluationofa15-valentpneumococcalconjugatevaccine(PCV15-CRM197)inaninfant-rhesusmonkeyimmunogenicitymodel[J].Vaccine,2011,29(48):8870-8876.DOI: 10.1016/j.vaccine.2011.09.078.
    [112] 林铃.肺炎球菌疫苗新策略[J].国际生物制品学杂志,2006,29(1):5-7.DOI: 10.3760/cma.j.issn.1673-4211.2006.01.003.LinL.Newstrategyforpneumococcalvaccine[J].IntJBiol,2006,29(1):5-7.DOI:10.3760/cma.j.issn.1673-4211.2006.01.003.
    [113] BrilesDE,AdesE,PatonJC,etal.IntranasalimmunizationofmicewithamixtureofthepneumococcalproteinsPsaAandPspAishighlyprotectiveagainstnasopharyngealcarriageofStreptococcuspneumoniae[J].InfectImmun,2000,68(2):796-800.DOI: 10.1128/IAI.68.2.796-800.2000.
    [114] BrilesDE,HollingsheadS,Brooks-WalterA,etal.ThepotentialtousePspAandotherpneumococcalproteinstoelicitprotectionagainstpneumococcalinfection[J].Vaccine,2000,18(16):1707-1711.DOI: 10.1016/S0264-410X(99)00511-3.
    [115] CaoJ,ChenDP,XuWC,etal.EnhancedprotectionagainstpneumococcalinfectionelicitedbyimmunizationwiththecombinationofPspA,PspC,andClpP[J].Vaccine,2007,25(27):4996-5005.DOI: 10.1016/j.vaccine.2007.04.069.
    [116] LeeLH,LeeCJ,FraschCE.Developmentandevaluationofpneumococcalconjugatevaccines:clinicaltrialsandcontroltests[J].CritRevMicrobiol,2002,28(1):27-41.DOI: 10.1080/1040-840291046678.
    [117] 王一平.转化缺失的无荚膜肺炎链球菌作为活疫苗候选菌株的安全性及保护效果评价研究[D].重庆:重庆医科大学,2013.WangYP.TheexperimentalresearchonsaftyandprotectiveefficacyofaseriesoftransformationdefectednoncapsulatedStreptococcuspneumoniaestrainsasattenuatedlivevaccinecandidates[D].Chongqing:ChongqingMedicalUniversity,2013.
    [118] JdarL,ButlerJ,CarloneG,etal.Serologicalcriteriaforevaluationandlicensureofnewpneumococcalconjugatevaccineformulationsforuseininfants[J].Vaccine,2003,21(23):3265-3272.DOI: 10.1016/S0264-410X(03)00230-5.
    [119] NunesMC,MadhiSA.ReviewontheimmunogenicityandsafetyofPCV-13ininfantsandtoddlers[J].ExpertRevVaccines,2011,10(7):951-980.DOI: 10.1586/erv.11.76.
    [120] WysockiJ,BrzostekJ,SzymańskiH,etal.Immunogenicityandsafetyofa13-valentpneumococcalconjugatevaccineadministeredtoolderinfantsandchildrennaivetopneumococcalvaccination[J].Vaccine,2015,33(14):1719-1725.DOI: 10.1016/j.vaccine.2015.02.005.
    [121] FrenckRJr,ThompsonA,YehSH,etal.Immunogenicityandsafetyof13-valentpneumococcalconjugatevaccineinchildrenpreviouslyimmunizedwith7-valentpneumococcalconjugatevaccine[J].PediatrInfectDisJ,2011,30(12):1086-1091.DOI: 10.1097/INF.0b013e3182372c6a.
    [122] GrimprelE,LaudatF,BakerS,etal.Safetyandimmunogenicityofa13-valentpneumococcalconjugatevaccinegivenwithroutinepediatricvaccinationtohealthychildreninFrance[C]//Proceedingsofthe27thAnnualMeetingoftheEuropeanSocietyforPaediatricInfectiousDisease.Brussels,Belgium:ESPID,2009.
    [123] SilfverdalSA,FlodmarkCE,RomboL,etal.13-valentpneumococcalconjugatevaccine(PCV13)inchildrenpartiallyimmunizedwith7-valentpneumococcalconjugatevaccine(PCV7):aphase3,open-labeltrial[J].Vaccine,2013,31(9):1284-1292.DOI: 10.1016/j.vaccine.2012.12.066.
    [124] JacksonLA,GurtmanA,vanCleeffM,etal.Immunogenicityandsafetyofa13-valentpneumococcalconjugatevaccinecomparedtoa23-valentpneumococcalpolysaccharidevaccineinpneumococcalvaccine-naiveadults[J].Vaccine,2013,31(35):3577-3584.DOI: 10.1016/j.vaccine.2013.04.085.
    [125] GreenbergRN,GurtmanA,FrenckRW,etal.Sequentialadministrationof13-valentpneumococcalconjugatevaccineand23-valentpneumococcalpolysaccharidevaccineinpneumococcalvaccine-naveadults60-64yearsofage[J].Vaccine,2014,32(20):2364-2374.DOI: 10.1016/j.vaccine.2014.02.002.
    [126] JacksonLA,GurtmanA,vanCleeffM,etal.Influenceofinitialvaccinationwith13-valentpneumococcalconjugatevaccineor23-valentpneumococcalpolysaccharidevaccineonantipneumococcalresponsesfollowingsubsequentpneumococcalvaccinationinadults50yearsandolder[J].Vaccine,2013,31(35):3594-3602.DOI: 10.1016/j.vaccine.2013.04.084.
    [127] GoldblattD,SouthernJ,AndrewsN,etal.Theimmunogenicityof7-valentpneumococcalconjugatevaccineversus23-valentpolysaccharidevaccineinadultsaged50-80years[J].ClinInfectDis,2009,49(9):1318-1325.DOI: 10.1086/606046.
    [128] MiernykKM,ButlerJC,BulkowLR,etal.Immunogenicityandreactogenicityofpneumococcalpolysaccharideandconjugatevaccinesinalaskanativeadults55-70yearsofage[J].ClinInfectDis,2009,49(2):241-248.DOI: 10.1086/599824.
    [129] KolibabK,SmithsonSL,ShrinerAK,etal.Immuneresponsetopneumococcalpolysaccharides4and14inelderlyandyoungadults.IAntibodyconcentrations,avidityandfunctionalactivity[J].ImmunAgeing,2005,2:10.DOI: 10.1186/1742-4933-2-10.
    [130] CarsonPJ,NicholKL,O'BrienJ,etal.Immunefunctionandvaccineresponsesinhealthyadvancedelderlypatients[J].ArchInternMed,2000,160(13):2017-2024.DOI: 10.1001/archinte.160.13.2017.
    [131] Romero-SteinerS,MusherDM,CetronMS,etal.ReductioninfunctionalantibodyactivityagainstStreptococcuspneumoniaeinvaccinatedelderlyindividualshighlycorrelateswithdecreasedIgGantibodyavidity[J].ClinInfectDis,1999,29(2):281-288.DOI: 10.1086/520200.
    [132] ArtzAS,ErshlerWB,LongoDL.Pneumococcalvaccinationandrevaccinationofolderadults[J].ClinMicrobiolRev,2003,16(2):308-318.DOI: 10.1128/CMR.16.2.308-318.2003.
    [133] BrandoAP,deOliveiraTC,deCuntoBrandileoneMC,etal.Persistenceofantibodyresponsetopneumococcalcapsularpolysaccharidesinvaccinatedlongterm-careresidentsinBrazil[J].Vaccine,2004,23(6):762-768.DOI: 10.1016/j.vaccine.2004.07.024.
    [134] SimonsenV,BrandoAP,BrandileoneMCC,etal.Immunogenicityofa23-valentpneumococcalpolysaccharidevaccineinBrazilianelderly[J].BrazJMedBiolRes,2005,38(2):251-260.DOI: 10.1590/S0100-879X2005000200014.
    [135] AhnJG,KimHW,ChoiHJ,etal.Functionalimmuneresponsestotwelveserotypesafterimmunizationwitha23-valentpneumococcalpolysaccharidevaccineinolderadults[J].Vaccine,2015,33(38):4770-4775.DOI: 10.1016/j.vaccine.2015.08.002.
    [136] TrlingJ,HedlundJ,KonradsenHB,etal.Revaccinationwiththe23-valentpneumococcalpolysaccharidevaccineinmiddleagedandelderlypersonspreviouslytreatedforpneumonia[J].Vaccine,2003,22(1):96-103.DOI: 10.1016/S0264-410X(03)00521-8.
    [137] LacknerTE,HamiltonRG,HillJJ,etal.Pneumococcalpolysacchariderevaccination:immunoglobulingseroconversion,persistence,andsafetyinfrail,chronicallyilloldersubjects[J].JAmGeriatrSoc,2003,51(2):240-245.DOI: 10.1046/j.1532-5415.2003.51064.x.
    [138] KoskelaM,LeinonenM,HaivaVM,etal.Firstandseconddoseantibodyresponsestopneumococcalpolysaccharidevaccineininfants[J].PediatrInfectDis,1986,5(1):45-50.
    [139] TempleK,GreenwoodB,InskipH,etal.AntibodyresponsetopneumococcalcapsularpolysaccharidevaccineinAfricanchildren[J].PediatrInfectDisJ,1991,10(5):386-390.
    [140] SellSH,WrightPF,VaughnWK,etal.Clinicalstudiesofpneumococcalvaccinesininfants.Ⅰ.Reactogenicityandimmunogenicityoftwopolyvalentpolysaccharidevaccines[J].RevInfectDis,1981,3Suppl:S97-S107.
    [141] RoseM,HeyC,KujumdshievS,etal.Immunogenicityofpneumococcalvaccinationofpatientswithcochlearimplants[J].JInfectDis,2004,190(3):551-557.DOI: 10.1086/422395.
    [142] HeyC,RoseMA,KujumdshievS,etal.Doesthe23-valentpneumococcalvaccineprotectcochlearimplantrecipients?[J].Laryngoscope,2005,115(9):1586-1590.DOI: 10.1097/01.mlg.0000171016.82850.41.
    [143] LeeHJ,KangJH,HenrichsenJ,etal.Immunogenicityandsafetyofa23-valentpneumococcalpolysaccharidevaccineinhealthychildrenandinchildrenatincreasedriskofpneumococcalinfection[J].Vaccine,1995,13(16):1533-1538.DOI: 10.1016/0264-410X(95)00093-G.
    [144] KongYJ,ZhangW,JiangZW,etal.Immunogenicityandsafetyofa23-valentpneumococcalpolysaccharidevaccineinChinesehealthypopulationaged2years:Arandomized,double-blinded,activecontrol,phaseⅢtrial[J].HumVaccinImmunother,2015,11(10):2425-2433.DOI: 10.1080/21645515.2015.1055429.
    [145] U.S.FDA.Approvedvaccineproducts.Prevnar13[EB/OL].[2018-01-18].https://www.fda.gov/biologicsbloodvaccines/vaccines/approvedproducts/default.htm.
    [146] EMA.Assessmentreportfor:prevenar13[R/OL].No.EMEA/H/C/001104.EMA,2009.http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001104/WC500057250.pdf.
    [147] SongJY,CheongHJ,TsaiTF,etal.ImmunogenicityandsafetyofconcomitantMF59-adjuvantedinfluenzavaccineand23-valentpneumococcalpolysaccharidevaccineadministrationinolderadults[J].Vaccine,2015,33(36):4647-4652.DOI: 10.1016/j.vaccine.2015.05.003.
    [148] AgarwalN,OllingtonK,KaneshiroM,etal.Areimmunosuppressivemedicationsassociatedwithdecreasedresponsestoroutineimmunizations?Asystematicreview[J].Vaccine,2012,30(8):1413-1424.DOI: 10.1016/j.vaccine.2011.11.109.
    [149] KumarD,WelshB,SiegalD,etal.Immunogenicityofpneumococcalvaccineinrenaltransplantrecipients-threeyearfollow-upofarandomizedtrial[J].AmJTransplant,2007,7(3):633-638.DOI: 10.1111/j.1600-6143.2007.01668.x.
    [150] McCashlandTM,PreheimLC,Gentry-NielsenMJ.Pneumococcalvaccineresponseincirrhosisandlivertransplantation[J].JInfectDis,2000,181(2):757-760.DOI: 10.1086/315245.
    [151] NordyT,HusebekkA,AabergeIS,etal.Humoralimmunitytoviralandbacterialantigensinlymphomapatients4-10yearsafterhigh-dosetherapywithABMT.SerologicalresponsestorevaccinationsaccordingtoEBMTguidelines[J].BoneMarrowTransplant,2001,28(7):681-687.DOI: 10.1038/sj.bmt.1703228.
    [152] SinisaloM,VilpoJ,ItlM,etal.Antibodyresponseto7-valentconjugatedpneumococcalvaccineinpatientswithchroniclymphocyticleukaemia[J].Vaccine,2007,26(1):82-87.DOI: 10.1016/j.vaccine.2007.10.053.
    [153] DransfieldMT,HarndenS,BurtonRL,etal.Long-termcomparativeimmunogenicityofproteinconjugateandfreepolysaccharidepneumococcalvaccinesinchronicobstructivepulmonarydisease[J].ClinInfectDis,2012,55(5):e35-44.DOI: 10.1093/cid/cis513.
    [154] MahmoodiM,AghamohammadiA,RezaeiN,etal.Antibodyresponsetopneumococcalcapsularpolysaccharidevaccinationinpatientswithchronickidneydisease[J].EurCytokineNetw,2009,20(2):69-74.DOI: 10.1684/ecn.2009.0153.
    [155] ButlerJC,BreimanRF,CampbellJF,etal.Pneumococcalpolysaccharidevaccineefficacy.Anevaluationofcurrentrecommendations[J].JAMA,1993,270(15):1826-1831.DOI: 1001/jama.1993.03510150060030.
    [156] SmetsF,BourgoisA,VermylenC,etal.Randomisedrevaccinationwithpneumococcalpolysaccharideorconjugatevaccineinasplenicchildrenpreviouslyvaccinatedwithpolysaccharidevaccine[J].Vaccine,2007,25(29):5278-5282.DOI: 10.1016/j.vaccine.2007.05.014.
    [157] LinPL,MichaelsMG,GreenM,etal.SafetyandimmunogenicityoftheAmericanAcademyofPediatrics-recommendedsequentialpneumococcalconjugateandpolysaccharidevaccinescheduleinpediatricsolidorgantransplantrecipients[J].Pediatrics,2005,116(1):160-167.DOI: 10.1542/peds.2004-2312.
    [158] AdamkiewiczTV,SilkBJ,HowgateJ,etal.Effectivenessofthe7-valentpneumococcalconjugatevaccineinchildrenwithsicklecelldiseaseinthefirstdecadeoflife[J].Pediatrics,2008,121(3):562-569.DOI: 10.1542/peds.2007-0018.
    [159] ChanCY,MolrineDC,GeorgeS,etal.PneumococcalconjugatevaccineprimesforantibodyresponsestopolysaccharidepneumococcalvaccineaftertreatmentofHodgkin'sdisease[J].JInfectDis,1996,173(1):256-258.DOI: 10.1093/infdis/173.1.256.
    [160] GattringerR,WinklerH,RoedlerS,etal.Immunogenicityofacombinedscheduleof7-valentpneumococcalconjugatevaccinefollowedbya23-valentpolysaccharidevaccineinadultrecipientsofheartorlungtransplants[J].TransplInfectDis,2011,13(5):540-544.DOI: 10.1111/j.1399-3062.2011.00628.x.
    [161] BlackS,ShinefieldH,FiremanB,etal.Efficacy,safetyandimmunogenicityofheptavalentpneumococcalconjugatevaccineinchildren.NorthernCaliforniaKaiserPermanenteVaccineStudyCenterGroup[J].PediatrInfectDisJ,2000,19(3):187-195.
    [162] LuceroMG,DulaliaVE,NillosLT,etal.Pneumococcalconjugatevaccinesforpreventingvaccine-typeinvasivepneumococcaldiseaseandX-raydefinedpneumoniainchildrenlessthantwoyearsofage[J].CochraneDatabaseSystRev,2009,(4):CD004977.DOI: 10.1002/14651858.CD004977.pub2.
    [163] EskolaJ,KilpiT,PalmuA,etal.Efficacyofapneumococcalconjugatevaccineagainstacuteotitismedia[J].NEnglJMed,2001,344(6):403-409.DOI: 10.1056/NEJM200102083440602.
    [164] GrijalvaCG,NuortiJP,ArbogastPG,etal.DeclineinpneumoniaadmissionsafterroutinechildhoodimmunisationwithpneumococcalconjugatevaccineintheUSA:atime-seriesanalysis[J].Lancet,2007,369(9568):1179-1186.DOI: 10.1016/S0140-6736(07)60564-9.
    [165] MooreMR,Link-GellesR,SchaffnerW,etal.Effectofuseof13-valentpneumococcalconjugatevaccineinchildrenoninvasivepneumococcaldiseaseinchildrenandadultsintheUSA:analysisofmultisite,population-basedsurveillance[J].LancetInfectDis,2015,15(3):301-309.DOI: 10.1016/S1473-3099(14)71081-3.
    [166] DemczukWHB,MartinI,GriffithA,etal.SerotypedistributionofinvasiveStreptococcuspneumoniaeinCanadaaftertheintroductionofthe13-valentpneumococcalconjugatevaccine,2010-2012[J].CanJMicrobiol,2013,59(12):778-788.DOI: 10.1139/cjm-2013-0614.
    [167] WaightPA,AndrewsNJ,LadhaniSN,etal.Effectofthe13-valentpneumococcalconjugatevaccineoninvasivepneumococcaldiseaseinEnglandandWales4yearsafteritsintroduction:anobservationalcohortstudy[J].LancetInfectDis,2015,15(5):535-543.DOI: 10.1016/S1473-3099(15)70044-7.
    [168] HarboeZB,DalbyT,WeinbergerDM,etal.Impactof13-valentpneumococcalconjugatevaccinationininvasivepneumococcaldiseaseincidenceandmortality[J].ClinInfectDis,2014,59(8):1066-1073.DOI: 10.1093/cid/ciu524.
    [169] Ben-ShimolS,GreenbergD,Givon-LaviN,etal.Earlyimpactofsequentialintroductionof7-valentand13-valentpneumococcalconjugatevaccineonIPDinIsraelichildren5years:anactiveprospectivenationwidesurveillance[J].Vaccine,2014,32(27):3452-3459.DOI: 10.1016/j.vaccine.2014.03.065.
    [170] SimonsenL,TaylorRJ,Schuck-PaimC,etal.Effectof13-valentpneumococcalconjugatevaccineonadmissionstohospital2yearsafteritsintroductionintheUSA:atimeseriesanalysis[J].LancetRespirMed,2014,2(5):387-394.DOI: 10.1016/S2213-2600(14)70032-3.
    [171] AngoulvantF,LevyC,GrimprelE,etal.Earlyimpactof13-valentpneumococcalconjugatevaccineoncommunity-acquiredpneumoniainchildren[J].ClinInfectDis,2014,58(7):918-924.DOI: 10.1093/cid/ciu006.
    [172] PrezMC,AlgortaG,ChamorroF,etal.Changesinhospitalizationsforpneumoniaafteruniversalvaccinationwithpneumococcalconjugatevaccines7/13valentandHaemophilusinfluenzaetypebconjugatevaccineinaPediatricReferralHospitalinUruguay[J].PediatrInfectDisJ,2014,33(7):753-759.DOI: 10.1097/INF.0000000000000294.
    [173] Becker-DrepsS,AmayaE,LiuL,etal.Changesinchildhoodpneumoniaandinfantmortalityratesfollowingintroductionofthe13-valentpneumococcalconjugatevaccineinNicaragua[J].PediatrInfectDisJ,2014,33(6):637-642.DOI: 10.1097/INF.0000000000000269.
    [174] ZhaoAS,BoyleS,ButrymowiczA,etal.Impactof13-valentpneumococcalconjugatevaccineonotitismediabacteriology[J].IntJPediatrOtorhinolaryngol,2014,78(3):499-503.DOI: 10.1016/j.ijporl.2013.12.028.
    [175] KaplanSL,CenterKJ,BarsonWJ,etal.MulticentersurveillanceofStreptococcuspneumoniaeisolatesfrommiddleearandmastoidculturesinthe13-valentpneumococcalconjugatevaccineera[J].ClinInfectDis,2015,60(9):1339-1345.DOI: 10.1093/cid/civ067.
    [176] Ben-ShimolS,Givon-LaviN,LeibovitzE,etal.Near-eliminationofotitismediacausedby13-valentpneumococcalconjugatevaccine(PCV)serotypesinsouthernIsraelshortlyaftersequentialintroductionof7-valent/13-valentPCV[J].ClinInfectDis,2014,59(12):1724-1732.DOI: 10.1093/cid/ciu683.
    [177] OlarteL,HultenKG,LamberthL,etal.Impactofthe13-valentpneumococcalconjugatevaccineonchronicsinusitisassociatedwithStreptococcuspneumoniaeinchildren[J].PediatrInfectDisJ,2014,33(10):1033-1036.DOI: 10.1097/INF.0000000000000387.
    [178] CohenR,LevyC,BingenE,etal.Impactof13-valentpneumococcalconjugatevaccineonpneumococcalnasopharyngealcarriageinchildrenwithacuteotitismedia[J].PediatrInfectDisJ,2012,31(3):297-301.DOI: 10.1097/INF.0b013e318247ef84.
    [179] LoughlinAM,HsuK,SilverioAL,etal.DirectandindirecteffectsofPCV13onnasopharyngealcarriageofPCV13uniquepneumococcalserotypesinMassachusetts'children[J].PediatrInfectDisJ,2014,33(5):504-510.DOI: 10.1097/INF.0000000000000279.
    [180] vanHoekAJ,SheppardCL,AndrewsNJ,etal.PneumococcalcarriageinchildrenandadultstwoyearsafterintroductionofthethirteenvalentpneumococcalconjugatevaccineinEngland[J].Vaccine,2014,32(34):4349-4355.DOI: 10.1016/j.vaccine.2014.03.017.
    [181] ShapiroED,BergAT,AustrianR,etal.Theprotectiveefficacyofpolyvalentpneumococcalpolysaccharidevaccine[J].NEnglJMed,1991,325(21):1453-1460.DOI: 10.1056/NEJM199111213252101.
    [182] MoberleyS,HoldenJ,TathamDP,etal.Vaccinesforpreventingpneumococcalinfectioninadults[J].CochraneDatabaseSystRev,2008,(1):CD000422.DOI: 10.1002/14651858.CD000422.pub2.
    [183] HussA,ScottP,StuckAE,etal.Efficacyofpneumococcalvaccinationinadults:ameta-analysis[J].CMAJ,2009,180(1):48-58.DOI: 10.1503/cmaj.080734.
    [184] MelegaroA,EdmundsWJ.The23-valentpneumococcalpolysaccharidevaccine.PartI.EfficacyofPPVintheelderly:acomparisonofmeta-analyses[J].EurJEpidemiol,2004,19(4):353-363.DOI: 10.1023/B:EJEP.0000024701.94769.98.
    [185] JacksonLA,NeuzilKM,YuO,etal.Effectivenessofpneumococcalpolysaccharidevaccineinolderadults[J].NEnglJMed,2003,348(18):1747-1755.DOI: 10.1056/NEJMoa022678.
    [186] ChristensonB,PauksenK,SylvanSP.Effectofinfluenzaandpneumococcalvaccinesinelderlypersonsinyearsoflowinfluenzaactivity[J].VirolJ,2008,5:52.DOI: 10.1186/1743-422X-5-52.
    [187] FrenchN,GordonSB,MwalukomoT,etal.Atrialofa7-valentpneumococcalconjugatevaccineinHIV-infectedadults[J].NEnglJMed,2010,362(9):812-822.DOI: 10.1056/NEJMoa0903029.
    [188] ManoffSB,LissC,CaulfieldMJ,etal.Revaccinationwitha23-valentpneumococcalpolysaccharidevaccineinduceselevatedandpersistentfunctionalantibodyresponsesinadultsaged65years[J].JInfectDis,2010,201(4):525-533.DOI: 10.1086/651131.
    [189] SteensA,VestrheimDF,AabergeIS,etal.Areviewoftheevidencetoinformpneumococcalvaccinerecommendationsforriskgroupsaged2yearsandolder[J].EpidemiolInfect,2014,142(12):2471-2482.DOI: 10.1017/S0950268814001514.
    [190] LiRC,LiFX,LiYP,etal.Safetyandimmunogenicityofa7-valentpneumococcalconjugatevaccine(PrevenarTM):primarydosingseriesinhealthyChineseinfants[J].Vaccine,2008,26(18):2260-2269.DOI: 10.1016/j.vaccine.2008.02.029.
    [191] 李荣成,李凤祥,李艳萍,等.7价肺炎球菌结合疫苗(沛儿TM)用于健康中国儿童加强免疫的安全性和免疫原性[J].中国疫苗和免疫,2009,15(3):196-200.LiRC,LiFX,LiYP,etal.Safetyandimmunogenicityofa7-valentpneumococcalconjugatevaccine(PrevenarTM)boosterdoseinhealthyChineseToddlers[J].ChinJVaccinesImmuniz,2009,15(3):196-200.
    [192] ZhuFC,HuYM,LiangQ,etal.Safetyandtolerabilityof13-valentpneumococcalconjugatevaccineinhealthyChineseadults,childrenandinfants[J].TherAdvDrugSaf,2015,6(6):206-211.DOI: 10.1177/2042098615613985.
    [193] AranaJE.Comparisonofpost-licensuresfetysurveillanceof13-valentpneumococcalconjugatevaccineand7-valentpneumococcalconjugatevaccine:datafromthevaccineadvereeventreportingsystem(Vaers)[D].Georgia:GeorgiaStateUniversity,2011.
    [194] HaberP,AranaJ,PilishviliT,etal.Post-licensuresurveillanceof13-valentpneumococcalconjugatevaccine(PCV13)inadultsaged19yearsoldintheUnitedStates,VaccineAdverseEventReportingSystem(VAERS),June1,2012-December31,2015[J].Vaccine,2016,34(50):6330-6334.DOI: 10.1016/j.vaccine.2016.10.052.
    [195] DurandoP,RosselliR,CremonesiI,etal.Safetyandtolerabilityof13-valentpneumococcalconjugatevaccineintheelderly:anobservationalstudyinLiguriaRegion,Italy[J].HumVaccinImmunother,2015,11(1):172-177.DOI: 10.4161/hv.34420.
    [196] BerhaneY,WorkuA,DemissieM,etal.ChildrenwhoreceivedPCV-10vaccinefromatwo-dosevialwithoutpreservativearenotmorelikelytodevelopinjectionsiteabscesscomparedwiththosewhoreceivedpentavalent(DPT-HepB-Hib)vaccine:alongitudinalmulti-sitestudy[J].PLoSOne,2014,9(6):e97376.DOI: 10.1371/journal.pone.0097376.
    [197] BurtonDC,BigogoGM,AudiAO,etal.Riskofinjection-siteabscessamonginfantsreceivingapreservative-free,two-dosevialformulationofpneumococcalconjugatevaccineinKenya[J].PLoSOne,2015,10(10):e0141896.DOI: 10.1371/journal.pone.0141896.
    [198] 杨耀,栗克喜,宋绍忠,等.23价肺炎球菌多糖疫苗临床试验[J].预防医学情报杂志,2007,23(4):390-391.DOI: 10.3969/j.issn.1006-4028.2007.04.002.YangY,LiKX,SongSZ,etal.Clinicaleffectof23-valentpneumococcalpolysaccharidevaccine[J].JPrevMedInf,2007,23(4):390-391.DOI:10.3969/j.issn.1006-4028.2007.04.002.
    [199] 张岷,周本立,李文,等.23价肺炎球菌多糖疫苗Ⅳ期临床研究-大面积安全性观察[J].预防医学情报杂志,2013,29(9):798-800.ZhangM,ZhouBL,LiW,etal.Safetyinvestigateof23-valentpneumococcalpolysaccharidevaccine[J].JPrevMedInf,2013,29(9):798-800.
    [200] MillerER,MoroPL,CanoM,etal.Post-licensuresafetysurveillanceof23-valentpneumococcalpolysaccharidevaccineintheVaccineAdverseEventReportingSystem(VAERS),1990-2013[J].Vaccine,2016,34(25):2841-2846.DOI: 10.1016/j.vaccine.2016.04.021.
    [201] JacksonLA,NelsonJC,WhitneyCG,etal.AssessmentofthesafetyofathirddoseofpneumococcalpolysaccharidevaccineintheVaccineSafetyDatalinkpopulation[J].Vaccine,2006,24(2):151-156.DOI: 10.1016/j.vaccine.2005.07.066.
    [202] JacksonLA,BensonP,SnellerVP,etal.Safetyofrevaccinationwithpneumococcalpolysaccharidevaccine[J].JAMA,1999,281(3):243-248.DOI: 10.1001/jama.281.3.243.
    [203] 叶家楷,李克莉,许涤沙,等.中国2013年疑似预防接种异常反应信息管理系统数据分析[J].中国疫苗和免疫,2015,21(2):121-131,200.YeJK,LiKL,XuDS,etal.EvaluationoftheadverseeventsfollowingimmunizationinformationmanagementsysteminChina,2013[J].ChinJVaccinesImmuniz,2015,21(2):121-131,200.
    [204] 叶家楷,李克莉,许涤沙,等.中国2014年疑似预防接种异常反应信息管理系统监测数据分析[J].中国疫苗和免疫,2016,22(2):125-137.YeJK,LiKL,XuDS,etal.AnalysisofsurveillanceforadverseeventsfollowingimmunizationinChina,2014[J].ChinJVaccinesImmuniz,2016,22(2):125-137.
    [205] 武文娣,刘大卫,李克莉,等.中国2012年疑似预防接种异常反应监测数据分析[J].中国疫苗和免疫,2014,20(1):1-12,66.WuWD,LiuDW,LiKL,etal.AnalysisonsurveillancedataofadverseeventsfollowingimmunizationinChina,2012[J].ChinJVaccinesImmuniz,2014,20(1):1-12,66.
    [206] 武文娣,刘大卫,李克莉,等.中国2010年疑似预防接种异常反应监测数据分析[J].中国疫苗和免疫,2012,18(5):385-397.WuWD,LiuDW,LiKL,etal.AnalysisonadverseeventsfollowingimmunizationsurveillanceinChina,2010[J].ChinJVaccinesImmuniz,2012,18(5):385-397.
    [207] 武文娣,李克莉,郑景山,等.中国2011年疑似预防接种异常反应监测数据分析[J].中国疫苗和免疫,2013,19(2):97-109.WuWD,LiKL,ZhengJS,etal.AnalysisonsurveillancedataofadverseeventsfollowingimmunizationinChina,2011[J].ChinJVaccinesImmuniz,2013,19(2):97-109.
    [208] DuffyJ,WeintraubE,HambidgeSJ,etal.FebrileSeizureriskaftervaccinationinChildren6to23Months[J].Pediatrics,2016,138(1):e20160320.DOI: 10.1542/peds.2016-0320.
    [209] CenterKJ,HansenJR,LewisE,etal.LackofassociationofKawasakidiseaseafterimmunizationinacohortofinfantsfollowedformultipleautoimmunediagnosesinalarge,phase-4observationaldatabasesafetystudyof7-valentpneumococcalconjugatevaccine:lackofassociationbetweenKawasakidiseaseandseven-valentpneumococcalconjugatevaccine[J].PediatrInfectDisJ,2009,28(5):438-440.DOI: 10.1097/INF.0b013e318196934a.
    [210] ThompsonA,GurtmanA,PattersonS,etal.Safetyof13-valentpneumococcalconjugatevaccineininfantsandchildren:Metaanalysisof13clinicaltrialsin9countries[J].Vaccine,2013,31(45):5289-5295.DOI: 10.1016/j.vaccine.2013.08.025.
    [211] TrottaF,RizzoC,SantuccioC,etal.Comparativesafetyevaluationof7-valentand13-valentpneumococcalvaccinesinroutinepaediatricvaccinationsinfourItalianregions,2009to2011[J].EuroSurveill,2015,20(7):21-28.
    [212] TsengHF,SyLS,LiuILA,etal.Postlicensuresurveillanceforpre-specifiedadverseeventsfollowingthe13-valentpneumococcalconjugatevaccineinchildren[J].Vaccine,2013,31(22):2578-2583.DOI: 10.1016/j.vaccine.2013.03.040.
    [213] LittlejohnES,ClothierHJ,PerrettKP,etal.Surveillanceofadverseeventsfollowingtheintroductionof13-valentpneumococcalconjugatevaccineininfants,andcomparisonwithadverseeventsfollowing7-valentpneumococcalconjugatevaccine,inVictoria,Australia[J].HumVaccinImmunother,2015,11(7):1828-1835.DOI: 10.1080/21645515.2015.1048937.
    [214] PartridgeS,AlveyJ,BernsteinH,etal.Safetyofacombinationdiphtheria,tetanustoxoid,acellularpertussis,hepatitisB,andinactivatedpoliovaccinecoadministeredwitha7-valentpneumococcalconjugatevaccineandaHaemophilusinfluenzaetypebconjugatevaccine[J].Vaccine,2007,25(10):1806-1813.DOI: 10.1016/j.vaccine.2006.11.008.
    [215] GhaffarF.Thesafetyof7-valentpneumococcalconjugatevaccine[J].ExpertOpinDrugSaf,2005,4(4):631-636.DOI: 10.1517/14740338.4.4.631.
    [216] BartonM,WasfyS,DipchandAI,etal.Seven-valentpneumococcalconjugatevaccineinpediatricsolidorgantransplantrecipients:aprospectivestudyofsafetyandimmunogenicity[J].PediatrInfectDisJ,2009,28(8):688-692.DOI: 10.1097/INF.0b013e31819d97be.
    [217] SaokaewS,RayanakornA,WuDBC,etal.Costeffectivenessofpneumococcalvaccinationinchildreninlow-andmiddle-incomecountries:asystematicreview[J].Pharmacoeconomics,2016,34(12):1211-1225.DOI: 10.1007/s40273-016-0439-3.
    [218] WuDBC,ChaiyakunaprukN,ChongHY,etal.Choosingbetween7-,10-and13-valentpneumococcalconjugatevaccinesinchildhood:areviewofeconomicevaluations(2006-2014)[J].Vaccine,2015,33(14):1633-1658.DOI: 10.1016/j.vaccine.2015.01.081.
    [219] InternationalVaccineAccessCenter.Globalvaccineintroductionandimplementation[EB/OL].[2018-01-03].http://www.jhsph.edu/research/centers-and-institutes/ivac/view-hub/ivac-viewhub-report-2017-march.pdf.
    [220] HuSL,ShiQ,SongSF,etal.Estimatingthecost-effectivenessofthe7-valentpneumococcalconjugatevaccineinShanghai,China[J].ValueHealthRegIss,2014,3:197-204.DOI: 10.1016/j.vhri.2014.04.007.
    [221] CaldwellR,RobertsCS,AnZJ,etal.Thehealthandeconomicimpactofvaccinationwith7-valentpneumococcalvaccine(PCV7)duringanannualinfluenzaepidemicandinfluenzapandemicinChina[J].BMCInfectDis,2015,15:284.DOI: 10.1186/s12879-015-1021-x.
    [222] MaurerKA,ChenHF,WagnerAL,etal.Cost-effectivenessanalysisofpneumococcalvaccinationforinfantsinChina[J].Vaccine,2016,34(50):6343-6349.DOI: 10.1016/j.vaccine.2016.10.051.
    [223] MoXT,TobeRG,LiuXY,etal.Cost-effectivenessandhealthbenefitsofpediatric23-valentpneumococcalpolysaccharidevaccine,7-valentpneumococcalconjugatevaccineandforecasting13-valentpneumococcalconjugatevaccineinChina[J].PediatrInfectDisJ,2016,35(11):e353-361.DOI: 10.1097/INF.0000000000001288.
    [224] 符一男,刘国恩,朱琳,等.七价肺炎链球菌结合疫苗预防肺炎链球菌性疾病的成本-效果分析[J].中国卫生经济,2013,32(1):49-52.DOI: 10.7664/CHE20130115.FuYN,LiuGE,ZhuL,etal.Cost-effectivenessanalysisofpneumococcalconjugate7-valuevaccineinChina[J].ChinHealthEconom,2013,32(1):49-52.DOI:10.7664/CHE20130115.
    [225] PorchiaBR,BonanniP,BechiniA,etal.Evaluatingthecostsandbenefitsofpneumococcalvaccinationinadults[J].ExpertRevVaccines,2017,16(2):93-107.DOI: 10.1080/14760584.2017.1242419.
    [226] OgilvieI,KhouryAE,CuiYD,etal.Cost-effectivenessofpneumococcalpolysaccharidevaccinationinadults:asystematicreviewofconclusionsandassumptions[J].Vaccine,2009,27(36):4891-4904.DOI: 10.1016/j.vaccine.2009.05.061.
    [227] 彭艳芹,余正,王国栋.老年人接种23价肺炎球菌多糖疫苗药物经济学研究的系统评价[J].中国药房,2015,26(36):5116-5118.DOI: 10.6039/j.issn.1001-0408.2015.36.27.PengYQ,YuZ,WangGD.Studyonthepharmacoeconomicsof23-valentpneumococcalpolysaccharidevaccineinelderly:asystem-aticreview[J].ChinaPharm,2015,26(36):5116-5118.DOI:10.6039/j.issn.1001-0408.2015.36.27.
    [228] ZhaoDJ,GaiTobeR,CuiM,etal.Cost-effectivenessofa23-valentpneumococcalpolysaccharidevaccineimmunizationprogrammefortheelderlyinShanghai,China[J].Vaccine,2016,34(50):6158-6165.DOI: 10.1016/j.vaccine.2016.11.003.
    [229] 刘聚源,纪文艳,吴疆.北京市老年人肺炎多糖疫苗接种成本效益分析[J].中国公共卫生,2011,27(2):191-193.LiuJY,JiWY,WuJ.Cost-benefitanalysisof23-valentpneumococcalpolysaccharidevaccineinelderlypopulationinBeijing[J].ChinJPublicHealth,2011,27(2):191-193.
    [230] 邱英鹏,赵琨,李雪,等.中国农村老年慢性阻塞性肺病患者接种23价肺炎多糖疫苗的卫生经济学评价[J].中华预防医学杂志,2016,50(12):1074-1078.DOI: 10.3760/cma.j.issn.0253-9624.2016.12.010.QiuYP,ZhaoK,LiX,etal.Healtheconomicevaluationofa23valuepneumococcalpolysaccharidevaccinationpilotprogrammeamongelderlychronicobstructivepulmonarydiseasepatientsinChina[J].ChinJPrevMed,2016,50(12):1074-1078.DOI:10.3760/cma.j.issn.0253-9624.2016.12.010.
    [231] 王军毅.23价肺炎球菌多糖疫苗预防糖尿病病人呼吸道感染的成本效果分析[J].海峡药学,2013,25(6):274-275.DOI: 10.3969/j.issn.1006-3765.2013.06.185.WangJY.Cost-effectivenessanalysisof23-valentpneumococcalpolysaccharidevaccineagainstrespiratoryinfectionindiabeticpatients[J].StraitPharmaceutJ,2013,25(6):274-275.DOI:10.3969/j.issn.1006-3765.2013.06.185.
    [232] 王茂慈,王太平,杨绍明,等.23价肺炎球菌多糖疫苗和流行性感冒病毒裂解疫苗联合接种对老年人呼吸系统疾病防治效果观察与效益分析[J].中国疫苗和免疫,2010,16(3):229-232.WangMC,WangTP,YangSM,etal.Effectivenessof23-valentpenumococcalpolysaccharideandsplit-virusinfluenzavaccinestopreventrespiratorydiseasesforelderlypeople[J].ChinJVaccinesImmuniz,2010,16(3):229-232.
    [233] 徐英,董碧蓉.23价肺炎球菌多糖疫苗预防老年人下呼吸道感染的效果考察[J].中国计划免疫,2005,11(4):287-291.DOI: 10.3969/j.issn.1006-916X.2005.04.011.XuY,DongBR.Effectivenessof23-valentpneumococcalpolysaccharidevaccinetopreventLRTIsintheelderlypopulation[J].ChinJVaccinesImmuniz,2005,11(4):287-291.DOI:10.3969/j.issn.1006-916X.2005.04.011.
    [234] 杨明常,李跃飞.慢性阻塞性肺病患者接种23价肺炎球菌多糖疫苗的成本-效益分析[J].广州医学院学报,2011,39(3):68-71.DOI: 10.3969/j.issn.1008-1836.2011.03.018.YangMC,LiYF.Acost-benefitanalysisonuseof23-valentpneumococcalpolysaccharidevaccine(PPV23)inpatientswithCOPD[J].AcadJGuangzhouMedColl,2011,39(3):68-71.DOI:10.3969/j.issn.1008-1836.2011.03.018.
    [235] NuortiJP,WhitneyCG,CentersforDiseaseControlandPrevention.Preventionofpneumococcaldiseaseamonginfantsandchildrenuseof13-valentpneumococcalconjugatevaccineand23-valentpneumococcalpolysaccharidevaccine-recommendationsoftheAdvisoryCommitteeonImmunizationPractices(ACIP)[J].MMWRRecommRep,2010,59(RR-11):1-18.
    [236] CDC.Useof13-valentpneumococcalconjugatevaccineand23-valentpneumococcalpolysaccharidevaccineforadultswithimmunocompromisingconditions:recommendationsoftheAdvisoryCommitteeonImmunizationPractices(ACIP)[J].MMWRMorbMortalWklyRep,2012,61(40):816-819.
    [237] CDC.Useof13-valentpneumococcalconjugatevaccineand23-valentpneumococcalpolysaccharidevaccineamongchildrenaged6-18yearswithimmunocompromisingconditions:recommendationsoftheAdvisoryCommitteeonImmunizationPractices(ACIP)[J].MMWRMorbMortalWklyRep,2013,62(25):521-524.
    [238] CDC.Recommendedimmunizationschedulesforpersonsaged0through18years-unitedstates,2010[J].JAMA,2010,303(9):828.
    [239] 辉瑞医学信息网站.13价肺炎球菌多糖结合疫苗说明书[EB/OL].[2016-10-25].https://www.pfizermedicalinformation.cn/OpenDocument.aspx?DocumentID=a5025aa8-0085-4a96-8f78-d407aaef1debType=PackageInserts.Pfizermedicalinformation.cn.Introductionof13trivalentpolysaccharideconjugatevaccineofpneumococcus[EB/OL].[2016-10-25].https://www.pfizermedicalinformation.cn/OpenDocument.aspx?DocumentID=a5025aa8-0085-4a96-8f78-d407aaef1debType=PackageInserts.
    [240] 成都生物制品研究所有限责任公司.23价肺炎球菌多糖疫苗(惠益康)[EB/OL].(2015)[2018-01-18].http://www.cdibp.com/list.asp?menu=10submenu=30.ChengduInstituteofBiologicalProductsCo.,Ltd.23-valentpneumococcalpolysaccharidevaccine[EB/OL].(2015)[2018-01-18].http://www.cdibp.com/list.asp?menu=10submenu=30.
    [241] 云南沃森生物技术股份有限公司.23价肺炎球菌多糖疫苗[EB/OL].(2017)[2018-01-18].http://www.walvax.com/Info/5/6/index.aspx.WalvaxBiotechnologyCo.,Ltd.23-valentpneumococcalpolysaccharidevaccine[EB/OL].(2017)[2018-01-18].http://www.walvax.com/Info/5/6/index.aspx.
    [242] 默沙东(中国)有限公司.23价肺炎球菌多糖疫苗说明书[EB/OL].[2013-11-12].http://www.msdchina.com.cn/SiteCollectionDocuments/nmf.pdf.MerckCo.,Inc(China).Theinstructionof23-valentpneumococcalpolysaccharidevaccine[EB/OL].[2013-11-12].http://www.msdchina.com.cn/SiteCollectionDocuments/nmf.pdf.
    [243] RothDE,CaulfieldLE,EzzatiM,etal.Acutelowerrespiratoryinfectionsinchildhood:opportunitiesforreducingtheglobalburdenthroughnutritionalinterventions[J].BullWorldHealthOrgan,2008,86(5):356-364.
    [244] DheraniM,PopeD,MascarenhasM,etal.Indoorairpollutionfromunprocessedsolidfueluseandpneumoniariskinchildrenagedunderfiveyears:asystematicreviewandmeta-analysis[J].BullWorldHealthOrgan,2008,86(5):390-398.
    [245] RellerLB,WeinsteinMP,WernoAM,etal.Laboratorydiagnosisofinvasivepneumococcaldisease[J].ClinInfectDis,2008,46(6):926-932.DOI: 10.1086/528798.
    [246] WeinbergerDM,TrzcinskiK,LuYJ,etal.Pneumococcalcapsularpolysaccharidestructurepredictsserotypeprevalence[J].PLoSPathog,2009,5(6):e1000476.DOI: 10.1371/journal.ppat.1000476.
    [247] AlonsoDeVelascoE,VerheulAF,VerhoefJ,etal.Streptococcuspneumoniae:virulencefactors,pathogenesis,andvaccines[J].MicrobiolRev,1995,59(4):591-603.
    [248] MelinM,TrzcińskiK,AntonioM,etal.Serotype-relatedvariationinsusceptibilitytocomplementdepositionandopsonophagocytosisamongclinicalisolatesofStreptococcuspneumoniae[J].InfectImmun,2010,78(12):5252-5261.DOI: 10.1128/IAI.00739-10.
    [249] HyamsC,CamberleinE,CohenJM,etal.TheStreptococcuspneumoniaecapsuleinhibitscomplementactivityandneutrophilphagocytosisbymultiplemechanisms[J].InfectImmun,2010,78(2):704-715.DOI: 10.1128/IAI.00881-09.
    [250] ColesCL,KanungoR,RahmathullahL,etal.PneumococcalnasopharyngealcolonizationinyoungSouthIndianinfants[J].PediatrInfectDisJ,2001,20(3):289-295.
    [251] HortalM,AlgortaG,BlanchiI,etal.CapsulartypedistributionandsusceptibilitytoantibioticsofStreptococcuspneumoniaeclinicalstrainsisolatedfromUruguayanchildrenwithsystemicinfections.PneumococcusStudyGroup[J].MicrobDrugResist,1997,3(2):159-163.
    [252] ObaroSK.ProspectsforpneumococcalvaccinationinAfricanchildren[J].ActaTrop,2000,75(2):141-153.DOI: 10.1016/S0001-706X(99)00094-7.
    [253] LevineMM,LagosR,LevineOS,etal.EpidemiologyofinvasivepneumococcalinfectionsininfantsandyoungchildreninMetropolitanSantiago,Chile,anewlyindustrializingcountry[J].PediatrInfectDisJ,1998,17(4):287-293.
    [254] HausdorffWP,BryantJ,KloekC,etal.Thecontributionofspecificpneumococcalserogroupstodifferentdiseasemanifestations:implicationsforconjugatevaccineformulationanduse,partⅡ[J].ClinInfectDis,2000,30(1):122-140.DOI: 10.1086/313609.
    [255] FenollA,JadoI,ViciosoD,etal.StreptococcuspneumoniaeinchildreninSpain:1990-1999[J].ActaPaediatrSuppl,2000,89(435):44-50.
    [256] O'BrienKL,ShawJ,WeatherholtzR,etal.EpidemiologyofinvasiveStreptococcuspneumoniaeamongNavajochildrenintheerabeforeuseofconjugatepneumococcalvaccines,1989-1996[J].AmJEpidemiol,2004,160(3):270-278.DOI: 10.1093/aje/kwh191.
    [257] FraserD,Givon-LaviN,NatalyaB,etal.Adecade(1989-1998)ofpediatricinvasivepneumococcaldiseasein2populationsresidingin1geographiclocation:implicationsforvaccinechoice[J].ClinInfectDis,2001,33(4):421-427.DOI: 10.1086/321874.
    [258] Kaltoft,ZeuthenN,KonradsenHB.Epidemiologyofinvasivepneumococcalinfectionsinchildrenaged0-6yearsinDenmark:a19-yearnationwidesurveillancestudy[J].ActaPaediatrSuppl,2000,89(435):3-10.DOI: 10.1111/j.1651-2227.2000.tb00775.x.
    [259] DoitC,LoukilC,GeslinP,etal.PhenotypicandgeneticdiversityofinvasivepneumococcalisolatesrecoveredfromFrenchchildren[J].JClinMicrobiol,2002,40(8):2994-2998.DOI: 10.1128/JCM.40.8.2994-2998.2002.
    [260] SongJH,DaganR,KlugmanKP,etal.Therelationshipbetweenpneumococcalserotypesandantibioticresistance[J].Vaccine,2012,30(17):2728-2737.DOI: 10.1016/j.vaccine.2012.01.091.
    [261] WhitneyCG,FarleyMM,HadlerJ,etal.Increasingprevalenceofmultidrug-resistantStreptococcuspneumoniaeintheUnitedStates[J].NEnglJMed,2000,343(26):1917-1924.DOI: 10.1056/NEJM200012283432603.
    [262] HicksLA,ChienYW,TaylorTHJr,etal.OutpatientantibioticprescribingandnonsusceptibleStreptococcuspneumoniaeintheUnitedStates,1996-2003[J].ClinInfectDis,2011,53(7):631-639.DOI: 10.1093/cid/cir443.
    [263] MillarEV,O'BrienKL,WattJP,etal.Effectofcommunity-wideconjugatepneumococcalvaccineuseininfancyonnasopharyngealcarriagethrough3yearsofage:across-sectionalstudyinahigh-riskpopulation[J].ClinInfectDis,2006,43(1):8-15.DOI: 10.1086/504802.
    [264] HuangSS,PlattR,Rifas-ShimanSL,etal.Post-PCV7changesincolonizingpneumococcalserotypesin16Massachusettscommunities,2001and2004[J].Pediatrics,2005,116(3):e408-413.DOI: 10.1542/peds.2004-2338.
    [265] HennessyTW,SingletonRJ,BulkowLR,etal.Impactofheptavalentpneumococcalconjugatevaccineoninvasivedisease,antimicrobialresistanceandcolonizationinAlaskaNatives:progresstowardseliminationofahealthdisparity[J].Vaccine,2005,23(48/49):5464-5473.DOI: 10.1016/j.vaccine.2005.08.100.
    [266] MooreMR,HydeTB,HennessyTW,etal.Impactofaconjugatevaccineoncommunity-widecarriageofnonsusceptibleStreptococcuspneumoniaeinAlaska[J].JInfectDis,2004,190(11):2031-2038.DOI: 10.1086/425422.
  • 病媒生物监测预警研究进展_刘起勇.pdf
  • 加载中
计量
  • 文章访问数:  2596
  • HTML全文浏览量:  148
  • PDF下载量:  167
  • 被引次数: 0
出版历程
  • 收稿日期:  2018-02-10
  • 刊出日期:  2018-02-28

目录

    /

    返回文章
    返回

    在线交流

    防诈骗公告

    近期有不法分子以本刊编辑身份添加作者微信,请务必提高警惕!本刊关于稿件的一切事项通知均采用编辑部唯一邮箱(jbjc@icdc.cn)和座机(010-58900732)联系作者,且在录用稿件后仅收取版面费,无其他任何名目费用(如审稿费和加急费等),非编辑部邮箱发送的本刊收费用通知等均为诈骗,不要随意汇入款项!如有可疑及时致电编辑部核实确认!